RegenMed and OREF Launch MOTIV™: A Peer-Reviewed Real-World Evidence Library for Musculoskeletal Innovation

RegenMed, in partnership with the Orthopaedic Research and Education Foundation (OREF), has launched M.O.T.I.V.™ — a pioneering initiative to generate structured, peer-reviewed, and clinically meaningful real-world evidence (RWE) datasets across the full spectrum of musculoskeletal (MSK) conditions.

MSK disorders represent one of the largest global health burdens.  Nearly one-third of the world’s population will experience an MSK-related condition in their lifetime, from degenerative joint disease and traumatic injuries to bone cancers and rare genetic disorders such as osteogenesis imperfecta.  In the United States alone, MSK care costs are estimated to exceed $980 billion annually, nearly 5% of U.S. GDP.

Yet despite this immense cost, outcomes for patients remain inconsistent.  Scientific progress is slowed by reliance on traditional clinical trials, which are lengthy, expensive, and selective.  Meanwhile, insurers and government payers are placing new emphasis on outcomes tracking — such as Medicare’s penalties for providers who fail to collect long-term results on hip and knee replacements.

The Limitations of Today’s Data

While “real-world evidence” has become a buzzword in healthcare, the vast majority of available datasets are derived from electronic health records, insurance claims, or proprietary algorithms.  These sources, though large, are fragmented, unverifiable, and often lack correlation between diagnosis, treatment protocols, and long-term outcomes.

The result is evidence that fails to meet clinical utility standards, limiting its role in advancing precision care, improving health equity, oraccelerating innovation.

What Makes M.O.T.I.V.™ Different

The M.O.T.I.V.™ (Musculoskeletal Outcomes Through Informed Validation) program is designed to overcome these barriers.  Each dataset in the library is:

• ‍Peer-Reviewed by OREF: Every observational protocol is vetted by leading MSK research.‍
• Anatomically & Clinically Specific: Defined by one anatomical region, one pathology, one treatment protocol, and one standardized outcomes assessment.
• Validatable to Primary Sources: Built for transparency and trust, avoiding unverifiable big-data manipulation.‍
• Longitudinal & Fit-for-Purpose: Meeting FDA requirements for clinical and regulatory use.
• Statistically and Clinically Relevant: Designed to support meaningful insights that improve patient care

By setting a new standard for structured, verifiable real-world data, M.O.T.I.V.™ ensures that research and innovation in orthopaedics are both clinically rigorous and widely accessible.

Driving Value-Based Care and Innovation

The launch of M.O.T.I.V.™ marks a critical step toward achieving value-based care in musculoskeletal medicine.  By creating datasets that are trusted, transparent, and clinically actionable, RegenMed and OREF are empowering:

• Providers to benchmark treatments and improve patient outcomes.
• Insurers and payers to make evidence-based reimbursement decisions.
• Researchers to accelerate the path from lab to bedside.
• Patients to benefit from more equitable, data-driven care.

This initiative positions RegenMed and OREF at the forefront of a healthcare transformation — one where real-world evidence is no longer an aspiration, but a validated, practical tool for medical advancement.

‍